Mektovi (binimetinib) — United Healthcare
Low-grade serous carcinoma
Initial criteria
- Diagnosis of low-grade serous carcinoma
- Disease is recurrent
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Mektovi therapy
Approval duration
12 months